Compare Figs Inc (FIGS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Figs Inc trades at $10.14 (market cap $1.66B), while Vertex Pharmaceuticals Incorporated trades at $480.61 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 72.9× Figs Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| FIGS | VRTX | |
|---|---|---|
Market Cap | $1.66B | $121.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $529.59 |
52-Week Low | $5.81 | $366.54 |
Enterprise Value | $1.44B | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $9.72, down 2.8% today, amid bearish technical signals despite recent earnings beats. Revenue grew to $631M in 2025 with a 66.6% gross margin, but net cash flow remains negative. Analyst consensus is bullish with a $19.50 price target, though technical indicators show selling pressure with RSI at neutral levels and ADX signaling a strong downtrend.
The stock presents a growth opportunity with strong fundamentals and analyst support, but faces near-term technical headwinds and margin pressures from tariffs and freight costs. Investors should weigh the 100% upside to consensus target against execution risks and persistent negative cash flow trends.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
